We use innovative therapies
We work on the development of new therapies and treatments that are more effective and less aggressive, so that young cancer patients can benefit from the most advanced treatments.
- We were European pioneers in the use of intra-arterial chemotherapy inpatients with retinoblastoma to avoid loss of the eye.
- We were the first centre in Europe to use anti-GD2 immunotherapy for the treatment of high risk neuroblastoma, which increases survival by around 20%.
- We have conducted an international clinical trial for patients with diffuse brainstem glioma, a cancer that is currently incurable.
- We have been pioneers in the introduction of CART immunotherapy for B-cell lymphoblastic leukaemia.
- We have implemented a Precision Oncology platform to identify therapeutic targets in refractory cases.
- We have developed and conducted a clinical trial with an oncolytic virus to treat retinoblastoma.
At the vanguard of knowledge
We undertake research to improve the diagnosis and treatment of our patients. We have five research groups and are participating in a large number of clinical trials with the aim of finding a treatment for incurable tumours.
- We are one of the few centres in Europe with an exclusive paediatric tumour bank, which has great research potential.
- We are the first European centre to have developed an animal model of diffuse brainstem glioma.
- We systemically genetically sequence tumours in relapse.
- Our investigators have developed a nanofibre fabric for local treatment of cancer.
- We have 5 of our own approved clinical trials.
- We are studying genetic diversity within developmental tumours through the sequencing of individual cells from certain tumour types. This is a fundamental step in studying the evolution of the tumour's various cells and generating more knowledge of the complexity of these diseases.
- In 2015 we started a personalised medicine programme based on massive DNA sequencing carried out by the Centre Nacional d’Anàlisi Genòmica (CNAG - National Centre for Genomic Analysis).
- We have accreditation from the Innovative Therapies for Children with Cancer (ITCC) group, which allows us to access the most innovative treatments and to include our patients in pioneering clinical trials.
- Our research laboratory is fully integrated with the care team.
- We have a molecular biology laboratory that characterises all tumours in order to better classify them, make prognoses and seek targeted treatments.
- The Hopp-Kindertumorzentrum Heidelberg (KiTZ - Hopp Children's Cancer Center) has officially recognised our Status as 1st Level Molecular Diagnostics Facility for Low Grade Glioma in Children (LOGGIC) Core BioClinical Data Bank.
We give special attention to families and to the overall well-being of the patient
We offer comprehensive interdisciplinary care to children and young people with cancer, focussing always on preserving the patient's quality of life.
- We have a team of psychologists and psycho-oncologists and social workers who help the patient and their family through various programmes.
- All painful treatment, such as bone marrow aspirations or lumbar punctures are performed under deep sedation in the Outpatient Surgery Unit (UCA) to avoid causing the patient unnecessary pain and anxiety.
- Wherever possible, we use outpatient treatment in our Day Hospital, so that the patient can return home each day. On some occasions, a home care team treats the patient at home.
- Since 2019, we have had the Integrative Paediatric Oncology Unit (UOPI), which aims to improve patients' experience and quality of life through all phases of their treatment, using acupuncture, essential oils and nutrition techniques.
We offer personalised medicine
We understand that every patient is different because every tumour is different. For this reason, we carry out studies and molecular diagnosis on every tumour we treat to determine its characteristics. In this way, we can predict the prognosis of the disease and the best approach for each patient, and also make sure they reach adulthood without sequelae.
- Our laboratory offers all techniques for molecular diagnosis and the prognosis of the disease in order to create a personalised treatment plan.
- Our mission is to cure our patients' cancers, but also to ensure that they develop as expected and reach adult age without sequelae. Among other lines of work, we use cryopreservation of oocytes (eggs) and sperm in children who undergo cancer treatment that might compromise their fertility, so that one day they can become parents.
Psychosocial care, assistance and services
When any child arrives in the Oncology Area of SJD Barcelona Children's Hospital, our team of psychologists and social workers performs a comprehensive assessment of their family situation so that an action plan can be drawn up. This plan includes guidance about the services and/or assistance (economic, work-related, social, accommodation, etc.) they can access to help them handle their son or daughter's illness, and proposes appropriate actions on the part of our professionals.
To prepare this plan, our professionals count on the support of the Hospital Amic and Hospitality programmes, among others, something that makes our hospital stand out. They also work with Escola La Magnòlia, the hospital's own school under the Department of Education of the Autonomous Government of Catalonia, to ensure continuity of education for inpatients in Catalonia. In some situations, they coordinate with social services in the family's place of residence to guarantee continuity of care to the family when they are at home, as well as with patient associations.
Lastly, our team is also present as normal life resumes, which can be a moment of crisis for families after a long time outside the school and work environment.
We have access to all medical techniques to diagnose and treat our patients. The new Pediatric Cancer Center Barcelona, a new single-speciality centre for the benefit of children and adolescents with cancer and their families, is set to open in June 2022.
The centre will bring together the healthcare services aimed at children and adolescents with developmental cancer and their families in one single place, as well as spaces dedicated to research. It will be one of the leading international paediatric cancer centres.
The aim of the Pediatric Cancer Center Barcelona is to more effectively, efficiently and appropriately care for a large volume of patients, more than 400 new patients a year, which will make advances in research and treatment possible.
The centre will house, together in the same building, cutting-edge high-tech research laboratories for molecular and cellular diagnosis and prognosis, and will be capable of developing innovative, personalised advanced therapies.
Some data on the Pediatric Cancer Center Barcelona
The SJD Barcelona Children's Hospital's Oncology Department
The SJD Barcelona Children's Hospital's Oncology Department is the national reference centre of for the treatment of developmental cancer and an international reference centre for determined types of tumours.